Wyeth/Genetics Institute's Updated Web Site Goes Live

Nashville, Tenn., November 15, 2001 -- Wyeth/Genetics Institute launched today an updated version of its Web site, hemophiliavillage.com, at the 53rd Annual Meeting of the National Hemophilia Foundation.

Hemophiliavillage.com is designed specifically for use by the hemophilia community, and has been revised to include new information and services. The Web site also offers a new feature article each month, and an e-mail alert system that notifies enrolled individuals when the Web site is updated with new information.

• News & Events: Provides the latest news from Wyeth/Genetics Institute, and a calendar of important dates
• Programs & Services: Overviews Wyeth/Genetics Institute's programs, such as the Soozie Courter Sharing a Brighter Tomorrow Hemophilia Scholarship and the company's Hemophilia Patient Assistance Program^®
• Product Information: Offers general background and information about the manufacturing process of Wyeth/Genetics Institute's two hemophilia treatments, BeneFIX^® Coagulation Factor IX (Recombinant) and ReFacto^® Antihemophilic Factor (Recombinant)
• Information Resources: Lists other sources of information for the hemophilia community

Wyeth/Genetics Institute, the biotechnology research unit of Wyeth-Ayerst Laboratories based in Cambridge, Massachusetts, is engaged in the discovery, development, and commercialization of human pharmaceuticals through recombinant DNA and other technologies. Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE: AHP), is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular therapies, central nervous system drugs, anti-inflammatory agents, infectious disease, hemophilia, oncology, vaccines, and generic pharmaceuticals.

BeneFIX is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings. As with the intravenous administration of any protein product, common adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, or lethargy. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. Patients should be informed of the early symptoms and signs of hypersensitivity reactions. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any hypersensitivity reactions occur.

ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia). ReFacto is indicated for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown. As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, lethargy, or manifestations of allergic reactions. The remote possibility exists for hypersensitivity to non-human mammalian proteins.

American Home Products Corporation (NYSE: AHP) is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of prescription drugs and over-the-counter medications. It is also a leader in vaccines, biotechnology, and animal health care.

Back to News Archives